Finland· FI-REL-REL4891
Ibaril-S
A desoximetasone product, registered in Finland by Aventis Pharma Deutschland GmbH.
Checked against Fimea (Finland) on
Informational only — not a medical device.
The record
At a glance
Fimea (Finland)- Manufacturer
- Aventis Pharma Deutschland GmbH
- Country
- Finland (FI)
- ATC code
- D07XC02
- ATC class
- Desoximetasone
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
55 interactions on record for desoximetasone.
Graded by severity as the source publishes them — 55 minor. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Desoximetasone · interactions on record
55 records
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/bf9716db-d67d-4500-b635-4696d7a17e71 GET /v1/drugs/bf9716db-d67d-4500-b635-4696d7a17e71?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": null,
"form": "liuos päänahkaan",
"route": null,
"ddd_unit": null,
"strength": null,
"atc_label": "desoksimetasoni",
"ma_number": "9170",
"auth_status": "Myyntilupa peruuntunut",
"eu_ma_number": null,
"fimea_rel_id": "REL4891",
"authorised_at": "1985-12-18"
}See everything about desoximetasone.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.